These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 19386082

  • 1. Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation.
    Campistol JM, Cockwell P, Diekmann F, Donati D, Guirado L, Herlenius G, Mousa D, Pratschke J, San Millán JC.
    Transpl Int; 2009 Jul; 22(7):681-7. PubMed ID: 19386082
    [Abstract] [Full Text] [Related]

  • 2. Sirolimus in renal transplantation.
    Morath C, Arns W, Schwenger V, Mehrabi A, Fonouni H, Schmidt J, Zeier M.
    Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii61-viii65. PubMed ID: 17890266
    [Abstract] [Full Text] [Related]

  • 3. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.
    Knight RJ, Villa M, Laskey R, Benavides C, Schoenberg L, Welsh M, Kerman RH, Podder H, Van Buren CT, Katz SM, Kahan BD.
    Clin Transplant; 2007 Sep; 21(4):460-5. PubMed ID: 17645704
    [Abstract] [Full Text] [Related]

  • 4. The role and value of sirolimus administration in kidney and liver transplantation.
    Mehrabi A, Fonouni H, Kashfi A, Schmied BM, Morath Ch, Sadeghi M, Schemmer P, Encke J, Sauer P, Zeier M, Weitz J, Büchler MW, Schmidt J.
    Clin Transplant; 2006 Sep; 20 Suppl 17():30-43. PubMed ID: 17100699
    [Abstract] [Full Text] [Related]

  • 5. Sirolimus-based immunosuppression: present state of the art.
    Kahan BD.
    J Nephrol; 2004 Sep; 17 Suppl 8():S32-9. PubMed ID: 15599884
    [Abstract] [Full Text] [Related]

  • 6. [Consensus-recommendations for sirolimus in liver transplantation].
    Golling M, Becker T, Broelsch C, Candinas D, Faust D, Fischer L, Geissler E, Graeb C, Iberer F, Klupp J, Kraus T, Müller AR, Neuhaus P, Strassburg CP, Wolff M, Zülke C, Bechstein WO.
    Z Gastroenterol; 2004 Nov; 42(11):1333-40. PubMed ID: 15558447
    [Abstract] [Full Text] [Related]

  • 7. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ, Elliott EN, Knight RJ, Gaber LW, Gaber AO.
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [Abstract] [Full Text] [Related]

  • 8. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
    Kahan BD.
    Transplant Proc; 2008 Dec; 40(10 Suppl):S17-20. PubMed ID: 19100899
    [Abstract] [Full Text] [Related]

  • 9. Individualizing early use of sirolimus in renal transplantation.
    Rial Mdel C, Abbud-Filho M, Gonçalves RT, Martinez-Mier G, Montero C, Raffaele P, Toledo Solares M, Alberú J.
    Transplant Proc; 2010 Dec; 42(10):4518-25. PubMed ID: 21168728
    [Abstract] [Full Text] [Related]

  • 10. Management of side effects of sirolimus therapy.
    Stallone G, Infante B, Grandaliano G, Gesualdo L.
    Transplantation; 2009 Apr 27; 87(8 Suppl):S23-6. PubMed ID: 19384183
    [Abstract] [Full Text] [Related]

  • 11. Rejection episodes and 3-year graft survival under sirolimus and tacrolimus treatment after adult intestinal transplantation.
    Lauro A, Dazzi A, Ercolani G, Zanfi C, Golfieri L, Amaduzzi A, Cucchetti A, La Barba G, Grazi GL, D'Errico A, Vivarelli M, Cescon M, Varotti G, Del Gaudio M, Ravaioli M, Di Simone M, Faenza S, Pironi L, Pinna AD.
    Transplant Proc; 2007 Jun 27; 39(5):1629-31. PubMed ID: 17580204
    [Abstract] [Full Text] [Related]

  • 12. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
    Albano L, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Blanc AS, Di Giambattista F, Dantal J, RAD A2420 Study Group.
    Transplantation; 2009 Jul 15; 88(1):69-76. PubMed ID: 19584683
    [Abstract] [Full Text] [Related]

  • 13. Sirolimus in pediatric renal transplantation.
    Kasap B.
    Pediatr Transplant; 2011 Nov 15; 15(7):673-85. PubMed ID: 22004542
    [Abstract] [Full Text] [Related]

  • 14. [Sirolimus offers advantages for kidney transplant patients].
    Med Klin (Munich); 2003 Feb 15; 98(2):VII. PubMed ID: 12638547
    [No Abstract] [Full Text] [Related]

  • 15. Out with the old, in with the new: immunosuppression minimization in children.
    Sarwal MM.
    Curr Opin Organ Transplant; 2008 Oct 15; 13(5):513-21. PubMed ID: 19060535
    [Abstract] [Full Text] [Related]

  • 16. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
    Wali RK, Weir MR.
    Curr Opin Organ Transplant; 2008 Dec 15; 13(6):614-21. PubMed ID: 19060552
    [Abstract] [Full Text] [Related]

  • 17. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy.
    Chapman JR, Valantine H, Albanell J, Arns WA, Campistol JM, Eisen H, Frigerio M, Lehmkuhl H, Marcen R, Morris R, Nashan B, Pascual J, Pohanka E, Segovia J, Zuckermann A.
    Transplant Proc; 2007 Dec 15; 39(10):2937-50. PubMed ID: 18089298
    [Abstract] [Full Text] [Related]

  • 18. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
    Campistol JM, Albanell J, Arns W, Boletis I, Dantal J, de Fijter JW, Mortensen SA, Neumayer HH, Øyen O, Pascual J, Pohanka E, Schena FP, Serón D, Sparacino V, Chapman JR.
    Nephrol Dial Transplant; 2007 May 15; 22 Suppl 1():i36-41. PubMed ID: 17456617
    [Abstract] [Full Text] [Related]

  • 19. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation.
    Zuckermann A, Manito N, Epailly E, Fiane A, Bara C, Delgado JF, Lehmkuhl H, Ross H, Eisen H, Chapman J, Valantine H.
    J Heart Lung Transplant; 2008 Feb 15; 27(2):141-9. PubMed ID: 18267219
    [Abstract] [Full Text] [Related]

  • 20. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview.
    Huyghe E, Zairi A, Nohra J, Kamar N, Plante P, Rostaing L.
    Transpl Int; 2007 Apr 15; 20(4):305-11. PubMed ID: 17326771
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.